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When comparing BMD with Vitek 2, only 44 (21%) had different 
MIC values with the vast majority (95%) different by only 1-well 
dilution. Overall, Vitek 2 results were more consistent with BMD, 
while standard Etest appeared to overestimate MICs when com-
pared with the standard method of BMD.
Clinical patient data were available for 187 patients 
(63 MRSA and 124 MSSA). There were no differences in median 
length of hospital stay, median hospital cost or all-cause mortality 
when comparing patients infected with a staphylococcal isolate with 
an MIC <1 µg/mL compared with those with an MIC ≥1 µg/mL 
or when comparing patients with MSSA versus MRSA bacteremia.
DISCUSSION
In the adult population, the trend during 2000–2005 toward 
increasing vancomycin MIC values for S. aureus,2,10 so-called 
“MIC creep,” has led to the concern that vancomycin may no longer 
be appropriate to treat invasive staphylococcal infection in adults 
where the MIC is ≥2 µg/mL. Furthermore, the increase in vancomy-
cin MICs has been associated with worse outcomes in adults with 
invasive S. aureus disease.4,5 We did not observe a similar trend in 
our pediatric population during the study period. Our data are con-
sistent with other reports in which a significant vancomycin MIC 
increase in pediatric populations was not demonstrated.6,7 There is 
not a clear explanation for the difference in MIC trends between 
children and adults. However, it may be related to differences in 
vancomycin usage (both frequency of use and dosing strategies) 
in children and adults leading to differences in resistance patterns 
of S. aureus. Our study is the first to specifically evaluate all blood 
isolates during a specified period.
We also evaluated the prevalence of heterogeneous vancomy-
cin-intermediate S. aureus in our pediatric population with invasive 
MRSA. Evaluation of the presence of vancomycin heteroresistance 
is challenging as there is a lack of standardized methodology for 
identification and the gold standard, population analysis profile to 
vancomycin exposure curve ratio (PAP-AUC), can be labor-inten-
sive and is typically unavailable in clinical laboratory settings. We 
used the Etest GRD method as a screening test to detect vancomy-
cin heteroresistance for all MRSA isolates in our population. This 
method has demonstrated relatively high specificity and sensitiv-
ity when compared with PAP-AUC, suggesting that it may be an 
adequate screening test.11 However, confirmation of positive tests by 
PAP-AUC is warranted. Although no vancomycin heteroresistance 
was identified among our isolates, observations should be confirmed 
in other pediatric populations because of the potentially associated 
clinical complications and poor outcomes reported in adult cases.
Storage of S. aureus isolates can potentially impact vancomy-
cin susceptibility results and is a recognized limitation of this study. 
Furthermore, results over a more extensive study period may poten-
tially demonstrate an increasing trend in vancomycin MICs. Finally, 
a larger sample size may be required to detect heteroresistance.
In our study, vancomycin MIC results varied across testing 
methods, with the standard Etest resulting in a higher value 94% 
of the time when compared with BMD. This could be problematic 
in clinical care as a falsely elevated vancomycin MIC may deter a 
clinician from using vancomycin in a scenario in which it would 
otherwise be the preferred first-line therapy. Therefore, it is essen-
tial for clinicians to be aware of the testing method used for sus-
ceptibility testing in their institution and consider MIC results in 
light of the method when selecting vancomycin as the preferred 
antimicrobial agent.
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Diarrhea is an important symptom of most enteric infections that are most frequent in children <5 years of age. In 1992, 
Bern et al1 published a review manuscript of studies from 1980s 
and reported 3.3 million deaths. They estimated 2–3 episodes of 
diarrhea per child of <5 years of age every year in developing 
countries. In 2003, Kosek et al2 published a review of the burden 
of diarrheal disease from reports between 1992 and 2000. They 
reported 3.2 episodes per child <5 years of age per year in develop-
ing countries and also estimated 2.5 million deaths (range: 2.1–4.7 
million), which was less than that in previous studies. In addition, 
the mortality rate of diarrhea disease was 4.9 per 1000 per year in 
the 1990s, which was decreased compared with reported previous 
studies. Bern et al1 reported 13.6 and 5.6 per 1000.
Agents that were recognized to cause diarrheal disease 
include bacteria, parasites and viruses. In developing countries, 
rotaviruses (RVs) are responsible of approximately 20% of diarrhea-
related deaths in children <5 years of age. Noroviruses (NoVs) and 
Sapoviruses (SaVs) of the Caliciviridae family also cause acute gas-
troenteritis (AGE). Currently, NoVs as emerging viruses are the most 
important cause of AGE, particularly in countries after introduction 
of universal RV vaccination. Many studies have shown that SaVs are 
important in outbreaks of sporadic gastroenteritis in children <5 years 
of age. Enteric adenoviruses (EAdVs), serotypes 40 and 41, are also 
associated with AGE. The frequency of EAdV-associated gastroen-
teritis varies considerably in the various studies and locations. Astro-
viruses (AstVs) also increasingly detected as another viral causing of 
gastroenteritis which reported in up to 10% of sporadic gastroenteri-
tis.3 Moreover, toroviruses and coronaviruses of the Coronaviridae 
family, human parechoviruses and Aichiviruses of the Picornaviridae 
family, and human bocavirus (HBoVs) of the Parvoviridae family 
are other viruses, which have been found to be associated with AGE.
Through improvement of the safety of drinking water and 
the disposal of sewage, the rate of nonviral gastroenteritis infec-
tions has decreased. Detection and management of viral AGE are 
considered high priority for the healthcare system, inlcuding Iran. 
In this review, all viral gastroenteritis studies in Iran were assessed 
to analyze the infection rate and association with enteric viruses.
METHODS
For this review, all published viral gastroenteritis studies from 
Iran were obtained by searches of Medline, PubMed and National 
databases. Search key words included: Viral gastroenteritis, diar-
rhea, Iran, rotavirus, norovirus, adenovirus, astrovirus, sapovirus, 
parechovirus and bocavirus. Overlapping data were excluded.
RESULTS
Data analysis of 22 gastroenteritis studies4–7 attributable 
to rotavirus estimated that prevalence of RV infection was 39.9% 
(Table 1). EAd40 and AAd41 viruses were detected in 5.7% of the 
stool samples in 9 published studies4,8–15 (Table 1). For NoVs and 
SaVs, positivity rates were on average 6.0% and 4.2% from 54,15–18 
and 3 studies,16,19,20 respectively. The prevalence of AstVs was 2.7% 
on average (5 studies)4,14,21–23 (Table 1). Another observation was 
that age and seasonal patterns of AGE due to virus infections in 
Iran were similar to each other. Viral infection occurred most often 
in children <2 years of age and during the cooler months.
In 2010, Nadji et al24 reported HBoVs isolation from 21.8% 
children with AGE. In 2012, Ghazi et al25 also showed that the 
incidence of human parechovirus 1 in children with AGE in Iran 
was 23.7%.
DISCUSSION
Considering that there have been few reports about burden 
of viral AGE in Iran, this review provides helpful information about 
frequency and circulation of viruses causing childhood AGE. RVs, 
NoVs, AdVs, SaVs and AstVs were all found to be involved as 
causes of AGE as well as human parechoviruses and HBoV.
Rotaviruses were the most prevalent viral agent causing 
AGE, consistent with findings in other regions in the world before 
the introduction of the RV vaccine.26 NoVs have been shown to 
be responsible for 70–90% of AGE outbreaks in Europe and the 
United States, respectively.18 The prevalence of NoV in Iran was 
6.0% which is close to data reported from neighboring countries 
such as Pakistan.18 However, the prevalence of NoV in some coun-
tries such as India, Iraq, Taiwan, Nicaragua, Brazil and Italy was 
12–48%,18 ie higher than in Iran. The detection rate of SaVs was 
not as high as that of NoVs in Iran, but it was consistent with rates 
in studies of other parts of the world.18 EAdVs were responsible for 
5.7% of AGE in children which is much lower than in Nigeria and 
close to that of epidemiologic reports of adenovirus detection in 
Brazil, Indonesia, Singapore and China.26 AstVs as cause of AGE 
in children which have a prevalence rate of 1.4–8.6% in different 
reports, but higher rates in Japan and Central America.26 In Iran, 
the prevalence of AstV was estimated to be 2.7%, similar to recent 
reports from Venezuela and Taiwan.26 In summary, this data analy-
sis suggests that SaVs and AstVs are minor causes of AGE in chil-
dren compared with RVs, NoVs and EAdVs.
In 2 studies, HBoV and human parechovirus 1 were detected 
in 21.8% and 23.7% of children with AGE, respectively. These 
reports were accordance to previous studies,26 but they need to con-
firm by further studies.
Overall, most studies assessed in this review have investi-
gated for only a single virus or a limited range of viruses. There-
fore, the true prevalence of viruses as cause of AGE and the real 
burden of viral AGE in Iran remain to be identified in carefully 
planned prospective studies with appropriate control groups. Fur-
thermore, genotyping should be carried out in such a study to iden-
tify the most frequent types of the different viruses responsible for 
the clinical burden of AGE in children in Iran.
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Interferon-gamma release assays (IGRAs) offer enhanced speci-ficity over the tuberculin skin test for the diagnosis of latent 
tuberculosis infection in some patient groups.1 The usage of IGRAs 
as a screening tool may be limited by indeterminate results, which 
have been found in up to two-thirds of immunocompromised chil-
dren.2 However, in immunocompetent children, disparate inde-
terminate ranges (0–35%) have been reported.3–5 These indeter-
minate results have primarily been due to failure of the negative 
control. The optimal interpretation of a real indeterminate result 
is unknown and indeterminates can arise for a number of reasons, 
including a generic lack of T-cell responses from a specific patient 
or to specimen handling and processing. One of the IGRAs, the 
QuantiFERON Gold In-Tube (QFT-GIT), requires vigorous shak-
ing of the tubes to ensure the mixing of blood with the antigens in 
the tubes.6 As most laboratory draws do not require such shaking, 
we hypothesized that inadequate training of hospital staff for an 
infrequently run assay may contribute to indeterminate results.
The goal of this investigation was to explore associations 
between indeterminate results and specimen collection procedures 
(using surrogate variables) for the QFT-GIT in a pediatric cohort.
MATERIALS AND METHODS
This was a retrospective study of children (0–18 years of 
age) in whom QFT-GIT were performed from July 2010 to August 
2011 at Texas Children’s Hospital (Houston, TX), a tertiary care 
facility serving a large population of immunocompromised chil-
dren. Children with indeterminate QFT-GIT were compared with 
children with determinate IGRAs—positive or negative. None of 
the children ultimately were treated for TB disease, and no chil-
dren had QFT-GIT done as part of a public health contact inves-
tigation. During the study period, the hospital had a standardized 
policy for inoculating tubes for QFT-GIT; this was available in 
the pathology online catalog, which was accessible through the 
hospital intranet on every computer workstation. These instruc-
tions stated that after inoculation of 1 mL blood into the 3 tubes 
needed for the QFT-GIT, the tubes should be mixed by shaking 
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